NKP608 is primarily investigated for its potential therapeutic applications in the field of neuropsychiatric disorders. It acts as a selective antagonist for the neurokinin-1 (NK1) receptor, which is implicated in the regulation of stress, anxiety, and depression. Research suggests that it may help alleviate symptoms of these conditions by modulating the activity of substance P, a neuropeptide involved in emotional and stress responses. Additionally, NKP608 has been explored for its potential role in reducing nausea and vomiting, particularly in the context of chemotherapy-induced side effects, due to its interaction with the NK1 receptor pathway. Its application in these areas is still under study, with a focus on understanding its efficacy and safety profile.